086900 - Medy-Tox, Inc.

086900 Summary

Biopharma

Stock Price & Overview

₩69,600 +300 (+0.43%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩69,600 ≈ US$50 · Market cap ₩0.5tn (≈ $363m)

086900 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Revenue	247.3	228.6	221.1	195.1	184.9	140.8	205.9	205.4	181.2	133.3	88.5
Cost of Revenue	104.0	89.6	87.2	68.7	79.0	66.5	69.5	54.2	34.6	24.1	14.2
Gross Profit	143.3	139.0	133.9	126.4	105.9	74.3	136.4	151.2	146.6	109.2	74.3
Selling, General & Administrative	126.3	118.7	116.5	79.7	71.4	111.4	110.7	65.7	59.7	34.0	22.7
Operating Income	17.0	20.3	17.3	46.7	34.5	-37.1	25.7	85.5	87.0	75.2	51.7
Finance Income	5.3	9.8	6.9	22.6	9.6	6.8	5.2	3.3	7.0	4.7	2.6
Finance Costs	9.3	10.0	8.8	11.7	8.1	13.4	4.3	3.8	8.0	4.4	1.3
Pretax Income	6.6	17.5	15.9	49.5	128.3	-42.1	25.1	85.1	85.2	75.0	52.0
Income Tax Expense	-9.1	1.4	6.2	12.9	35.0	-12.1	-0.4	15.3	15.3	15.8	9.7
Net Income	15.7	16.1	9.7	36.6	93.3	-30.0	25.6	69.8	70.0	59.2	42.3
Total Comprehensive Income	5.5	15.8	9.7	51.0	96.4	-32.0	24.8	67.8	69.0	59.2	42.2

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Assets	581.8	615.2	611.6	596.3	577.7	467.8	421.5	395.0	380.9	324.0	203.6
Current Assets	155.3	186.6	166.2	135.1	161.0	138.7	120.0	116.4	103.2	68.6	103.5
Cash & Cash Equivalents	48.9	46.2	33.2	20.7	71.8	44.0	20.0	19.2	26.4	15.8	27.2
Inventories	43.1	64.3	59.6	52.6	33.0	37.6	29.3	21.5	11.6	6.9	5.8
Trade Receivables	59.4	58.4	68.9	53.9	44.2	42.9	61.3	67.4	56.0	31.4	18.9
Non-current Assets	426.4	428.6	445.4	461.2	416.7	329.1	301.5	278.6	277.8	255.4	100.1
Property, Plant & Equipment	199.5	200.3	205.3	208.1	204.6	213.1	186.5	181.7	184.4	150.6	81.0
Intangible Assets	77.6	72.0	54.2	26.5	11.8	18.0	22.3	21.0	20.3	19.3	10.3
Total Liabilities	127.5	144.4	137.1	162.7	174.1	223.0	158.8	137.8	184.4	176.4	90.1
Current Liabilities	104.8	117.6	126.6	135.3	107.9	117.6	136.3	110.8	137.4	76.6	47.5
Non-current Liabilities	22.7	26.8	10.6	27.4	66.2	105.4	22.5	27.0	47.0	99.8	42.5
Total Equity	454.3	470.8	474.5	433.6	403.6	244.8	262.7	257.2	196.5	147.7	113.5
Share Capital	3.9	3.9	3.9	3.6	3.4	3.1	2.9	2.8	2.8	2.8	2.8
Retained Earnings	435.9	425.2	406.7	401.1	364.1	268.1	304.6	283.6	226.2	172.8	123.5

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Cash from Operating Activities	61.4	36.6	13.5	26.2	20.0	27.9	33.7	55.1	56.5	54.1	22.4
Cash from Investing Activities	-20.6	-0.6	13.3	-36.1	-27.8	-52.0	-28.4	-16.1	-38.2	-114.3	-7.5
Purchase of Property, Plant & Equipment	15.7	8.7	7.7	9.9	17.5	41.1	21.0	8.5	38.0	136.5	30.1
Cash from Financing Activities	-37.6	-24.0	-13.5	-40.4	34.8	50.7	-4.5	-46.0	-7.4	49.2	6.8
Dividends Paid	8.9	8.4	8.4	8.0	0.0	5.5	4.3	12.1	11.1	9.6	8.5
Net Change in Cash	2.9	12.2	13.2	-51.1	27.8	24.0	0.8	-7.1	10.6	-11.0	21.7

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	68.7	60.7	60.7	61.0	61.6	64.0	55.2	53.9	65.0	54.6
Cost of Revenue	27.6	18.9	24.5	24.6	29.0	25.9	22.0	22.5	23.6	21.5
Gross Profit	41.1	41.8	36.2	36.4	32.6	38.1	33.2	31.4	41.4	33.1
Selling, General & Administrative	36.3	34.4	39.9	27.5	26.3	32.6	32.2	25.4	27.0	34.0
Operating Income	4.8	7.4	-3.7	8.9	6.3	5.5	0.9	6.0	14.3	-0.9
Finance Income	2.0	3.7	2.3	0.8	1.3	0.9	5.8	0.4	1.5	2.1
Finance Costs	1.2	2.2	1.9	1.3	4.8	1.2	5.4	1.9	1.2	1.5
Pretax Income	4.3	9.7	-14.0	7.8	8.2	4.5	0.7	4.0	13.9	-1.1
Income Tax Expense	1.1	1.8	-10.9	0.6	0.1	1.2	-1.7	0.2	2.5	0.4
Net Income	3.1	7.9	-3.1	7.2	8.2	3.3	2.4	3.8	11.3	-1.5
Total Comprehensive Income	4.6	7.3	-1.4	2.7	0.3	4.0	-8.4	20.8	-17.0	20.3

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	571.9	564.8	581.8	586.9	581.4	603.2	615.2	625.5	613.9	633.5
Current Assets	158.2	146.2	155.3	170.7	159.2	175.9	186.6	161.2	164.5	162.1
Cash & Cash Equivalents	46.9	42.5	48.9	59.1	45.3	51.9	46.2	27.7	30.2	36.6
Inventories	39.3	45.4	43.1	46.4	49.1	59.0	64.3	64.4	62.5	61.3
Trade Receivables	66.7	52.4	59.4	59.0	59.0	58.2	58.4	62.6	66.8	58.5
Non-current Assets	413.6	418.6	426.4	416.2	422.2	427.3	428.6	464.3	449.4	471.3
Property, Plant & Equipment	—	197.6	199.5	194.7	196.9	198.4	200.3	199.5	201.3	201.1
Intangible Assets	82.7	79.4	77.6	82.6	78.7	73.9	72.0	59.4	61.6	59.2
Total Liabilities	192.5	185.1	127.5	119.3	116.5	138.5	144.4	126.9	136.2	138.7
Current Liabilities	153.0	144.7	104.8	95.6	88.3	112.2	117.6	119.0	128.8	130.2
Non-current Liabilities	39.5	40.4	22.7	23.7	28.1	26.3	26.8	7.9	7.4	8.5
Total Equity	379.3	379.7	454.3	467.7	464.9	464.7	470.8	498.6	477.7	494.8
Share Capital	3.9	3.9	3.9	3.9	3.9	3.9	3.9	3.9	3.9	3.9
Retained Earnings	367.6	363.7	435.9	447.6	440.2	432.5	425.2	419.5	415.7	405.0

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	9.2	24.4	15.8	19.0	9.8	16.8	15.7	12.1	-3.7	12.5
Cash from Investing Activities	0.8	2.6	-13.6	-6.3	-5.4	4.7	22.3	-2.7	-12.0	-8.2
Purchase of Property, Plant & Equipment	1.6	1.7	9.0	1.7	2.3	2.7	1.0	2.2	4.6	1.0
Cash from Financing Activities	-6.0	-33.7	-12.5	-0.6	-8.7	-15.9	-20.8	-11.5	9.5	-1.3
Dividends Paid	—	—	—	—	—	—	8.4	0.0	0.0	0.0
Net Change in Cash	3.9	-6.5	-10.7	12.4	-4.6	5.7	17.8	-2.5	-6.4	3.4

Consolidated (CFS), from DART. 11 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

086900 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	247.3	+8.2%	+8.2%	+11.9%	+10.8%
Operating income	17.0	-16.4%	-28.6%	—	-10.5%
Net income	15.7	-2.6%	-24.6%	—	-9.5%
EPS	₩2,146	-2.6%	-24.6%	—	-9.5%
Operating cash flow	61.4	+68.0%	+32.8%	+17.1%	+10.6%
Shareholders' equity	454.3	-3.5%	+1.6%	+13.2%	+14.9%

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

086900 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	57.9%	60.8%	60.5%	64.8%	57.3%	52.8%
Operating margin	6.9%	8.9%	7.8%	23.9%	18.7%	-26.3%
Net margin	6.3%	7.0%	4.4%	18.8%	50.4%	-21.3%
Return on equity	3.4%	3.4%	2.1%	8.7%	28.8%	-11.8%
Return on assets	2.6%	2.6%	1.6%	6.2%	17.8%	-6.8%
Operating cash flow / revenue	24.8%	16.0%	6.1%	13.4%	10.8%	19.8%
Capex / revenue	6.3%	3.8%	3.5%	5.1%	9.5%	29.2%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 086900

Symbol	Last Price
085660Chabiotech Co., Ltd.	₩8,090 +2.1%
476060Onconic Therapeutics, Inc.	₩16,440 -3.9%
041960Komipharm International Co., Ltd.	₩9,710 +3.5%
317450Myungin Pharm	₩44,650 +0.0%
001060JW Pharmaceutical	₩27,500 +1.3%
456160G2GBIO, Inc.	₩37,950 +5.7%
019170Shinpoong Pharmaceutical Co., Ltd.	₩10,010 -0.9%
358570GI Innovation, Inc.	₩8,090 +6.2%
397030April Bio Co., Ltd.	₩17,800 +6.1%
249420Ildong Pharm	₩15,030 -0.5%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.